IndexIQ Advisors’s Passage Bio PASG Stock Holding History

IndexIQ Advisors’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$402K	Buy	+6,478	New	+$534K	0.01%	653

Other funds holding PASG

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

IndexIQ Advisors's PASG Position: Q1 2022 in Review

IndexIQ Advisors opened a new position in Passage Bio (PASG) in Q1 2022: 6,478 shares worth $402K. The stake represents 0.01% of the portfolio and ranks #653 among its holdings.

108 funds tracked by Wall St. Rank hold PASG as of Q1 2022.

IndexIQ Advisors held 6,478 shares of Passage Bio worth $402K as of Q1 2022.
Passage Bio was a new IndexIQ Advisors position in Q1 2022.
Passage Bio made up 0.01% of IndexIQ Advisors's portfolio in Q1 2022, its #653 holding.
108 funds tracked by Wall St. Rank held Passage Bio as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.